



# reSET®/reSET-O®

on the 2023 Florida Medicaid Preferred Drug List

## reSET® and reSET-O®, from Pear Therapeutics, are now included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023.

reSET® and reSET-O®, are the first and only FDA-authorized prescription digital therapeutics (PDTs) for substance use disorder (SUD) and opioid use disorder (OUD), respectively, for adults (18 years and older) being treated in an outpatient treatment program.

reSET® and reSET-O® can be downloaded to the member's smartphone.



Monetary NDC: 96439-0011-01  
Non-monetary NDC: 96439-0012-01  
1 prescription per 90 days



Monetary NDC: 96439-0021-01  
Non-monetary NDC: 96439-0022-01  
1 prescription per 84 days

### Getting Started

reSET and reSET-O, available 24/7, use three treatment approaches that complement the work providers are already doing:

- 1 Cognitive Behavioral Therapy: Interactive cognitive behavioral therapy lessons that help you learn new skills and identify and change negative thoughts and behaviors to build a healthier life
- 2 Fluency Training: Quizzes that help you remember what you've learned
- 3 Contingency Management: Chances to earn gift card rewards† for completing lessons and having negative urine drug screens

### Providers

- > Just like a traditional drug, reSET® and reSET-O® require a provider prescription—the prescription is submitted by ERx, Pear Portal, or PDF Enrollment.
- > Virtual training, to support the prescribing process, can be accessed at: [www.resetforrecovery.com/training/pdf/landing/](http://www.resetforrecovery.com/training/pdf/landing/)
- > In addition, providers can contact PearConnect® at 1-833-697-3738 for product and technical support

### Members

- > PearConnect offers members' assistance with reSET and reSET-O, including personalized onboarding, product education, adherence check-ins, technical guidance, and support
- > PearConnect® can also help members with technical issues
- > Members can contact PearConnect® at 1-833-444-PEAR for product and technical support

# Important Safety Information

## reSET® Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

- increase abstinence from a patient's substances of abuse during treatment, and
- increase retention in the outpatient treatment program.

## reSET® Important Safety Information for Clinicians:

**Warnings:** reSET is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications)

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient's medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

Please see the [Clinician Brief Summary Instructions for reSET](#).

## REFERENCES:

1. reSET. Clinician directions for use. Boston, MA: Pear Therapeutics, Inc. 2020. 2. reSET-O. Clinician directions for use. Boston, MA: Pear Therapeutics, Inc. 2020.



[peartherapeutics.com](http://peartherapeutics.com)

reSET®, reSET-O® and Pear Therapeutics® are trademarks of Pear Therapeutics (US), Inc. ©2022 Pear Therapeutics (US), Inc. All rights reserved. MAV-0001-22\_09 | 09/2022

## reSET-O® Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

## reSET-O® Important Safety Information for Clinicians:

**Warnings/precautions:** reSET-O is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient's medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the [Clinician Brief Summary Instructions for reSET-O](#).